Voronoi Inc.

Voronoi Inc. (Korean: 보로노이) is a South Korean biopharmaceutical company focused on the discovery and development of small-molecule kinase inhibitors. The company is headquartered in Songdo, Incheon, a major hub of South Korea's national bio cluster, and maintains a U.S. presence in Boston for business development and clinical development. Voronoi's core scientific platform, VORONOMICS®, is an AI-driven drug design platform that integrates molecular modeling and structural biology to enhance drug selectivity and accelerate the discovery of development candidates. The company states that its platform can reduce the average time to develop a candidate to roughly 1–1.5 years, compared with 4–4.5 years for the industry. Voronoi's pipeline is centered on precision-designed kinase inhibitors intended to reach difficult targets, including brain penetration. Its lead programs include VRN11, a next-generation EGFR-targeted therapy being studied in lung cancer, and VRN10, a HER2-targeted therapy for breast cancer. The company has presented clinical data at major oncology conferences, including the World Conference on Lung Cancer (WCLC), and has pursued global clinical expansion, including regulatory approvals for trials in Thailand. Voronoi operates an integrated in-house R&D infrastructure that includes a Bio Lab, Medicinal Chemistry Research Lab, AI Lab, Preclinical Research Center, and Structural Analysis Lab. The company reports a large kinase full profiling database with more than 550,000 experimental data points generated annually, and it ranks highly in small-molecule drug patent filings. Voronoi is listed on the KOSDAQ market under the ticker 310210. Its leadership includes CEO Daekwon Kim (R&D) and CEO Hyuntae Kim (Corporate Management), along with a scientific advisory board featuring prominent oncology researchers.

Voronoi Inc. (Korean: 보로노이) is a South Korean drug discovery company that has built its identity around an AI-driven approach to small-molecule kinase inhibitor design. The company is headquartered in Songdo, Incheon, within South Korea's national bio cluster, and it maintains a U.S. base in Boston for business development and clinical development. Its scientific platform, VORONOMICS®, integrates molecular modeling and structural biology to enhance drug selectivity and to accelerate the identification and optimization of development candidates. According to the company, this approach can shorten the average time to a development candidate to roughly 1–1.5 years, compared with 4–4.5 years for the industry. Voronoi's research infrastructure is integrated in-house and includes a Bio Lab, a Medicinal Chemistry Research Lab, an AI Lab, a Preclinical Research Center, and a Structural Analysis Lab. The company reports a kinase full profiling database with more than 550,000 experimental data points generated annually, which it uses for target validation and candidate optimization. It also states that it ranks first in Korea and ninth globally in small-molecule drug patent filings under the Patent Cooperation Treaty as of March 2025. The company's pipeline focuses on precision-designed kinase inhibitors intended to reach difficult targets, including brain penetration. Its lead programs include VRN11, a next-generation EGFR-targeted therapy for lung cancer, and VRN10, a HER2-targeted therapy for breast cancer. Voronoi has pursued early clinical development (Phase 1–2) and has presented data at international oncology conferences. At the World Conference on Lung Cancer 2026 (WCLC 2026) in Seoul, the company presented Phase 1 results for VRN11, reporting differentiated antitumor effects in patients with C797S mutations and brain metastases. It also received approval in Thailand for a global Phase 1b/2 IND for VRN11. Voronoi is listed on the KOSDAQ market under the ticker 310210. The company has faced challenges in its business development history: in 2023, a U.S. partner terminated a technology licensing agreement for an anticancer candidate. The company continues to advance its internal pipeline and global clinical strategy, with leadership including CEO Daekwon Kim (R&D) and CEO Hyuntae Kim (Corporate Management), and a scientific advisory board that includes Pasi A. Jänne, M.D.-Ph.D., and Lillian L. Siu, M.D.

• A U.S. partner terminated a technology licensing agreement for an anticancer candidate.

• Voronoi ranked 1st in Korea and 9th globally in small-molecule drug patent filings (PCT).

• Received IND approval in Thailand for global Phase 1b/2 trial of VRN11.

• Presented Phase 1 results of VRN11 at WCLC 2026, showing differentiated antitumor effect in C797S and brain metastasis patients.

AI-driven precision kinase inhibitor drug discovery and early clinical development

• VRN11

  Next-generation EGFR-targeted therapy for lung cancer, designed for brain penetration and activity against C797S mutations.

• VRN10

  HER2-targeted therapy for breast cancer.

• VORONOMICS®

  AI-driven drug design platform integrating molecular modeling and structural biology to enhance drug selectivity.

1. 1VORONOI Official Websitevoronoi.io
2. 2About - Voronoivoronoi.io
3. 3Our-team - Voronoivoronoi.io
4. 4Voronoi Inc. - Wikidatawikidata.org
5. 5보로노이 - Wikipedia (Korean)ko.wikipedia.org